story of the week
FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer
Phase 3 trial data show 96.7 percent of patients who received Orgovyx achieved and maintained castrate levels of testosterone
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.